The Bottom line: A rare disorder, Acquired hemophilia A has an incidence of approximately 1 per million a year. The mortality rate is high at more than 20%. AHA occurs due to autoantibodies against coagulation factor VIII which results in severe, often life-threatening bleeding.
Shetty, Shrimati, Acquired hemophilia a: diagnosis, aetiology, clinical spectrum and treatment options. Autoimmunity reviews 2011 vol:10 iss:6 pg:311 -316
Patients with AHA are continually at risk of severe hemorrhage until complete eradication of the inhibitors. As patients present with sudden life-threatening bleeding, awareness and education of specialists, is important. Treatment procedures should be adapted to bleeding severity and inhibitor titre should always be managed jointly with a specialist centre.